Effects of Vitamin B3 in Patients With Ataxia Telangiectasia

Overview

This clinical trial investigates the effects of nicotinamide riboside (vitamin B3) on the disease course of patients with ataxia telangiectasia. Patients will be treated during four consecutive months with nicotinamide riboside (25mg/kg/day), followed by a washout period of two months. Main study parameters/endpoints: Ataxia, dysarthria, quality of life, laboratory parameters.

Full Title of Study: “Effects of Nicotinamide Riboside (Vitamin B3) in Patients With Ataxia Telangiectasia.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 1, 2019

Detailed Description

Rationale: Ataxia Telangiectasia (A-T) is an autosomal recessively inherited neurodegenerative disorder, with a high cancer risk, that also affects the immune and respiratory system. Therapy for A-T is restricted to symptomatic treatment including rehabilitation care, combined with infection prevention and treatment, and screening for pulmonary dysfunction and malignancies. A-T is caused by mutations in the ATM gene. The ATM protein plays a pivotal role in more than 100 different biochemical processes, among which cellular energy metabolism, cell signaling, and DNA repair. Nicotinamide adenine dinucleotide (NAD+) is an essential molecule in many of these processes and studies have shown that NAD+ deficiency plays a role in disease mechanisms underlying DNA repair disorders such as A-T. NAD+ is available in food, but can also be synthesized in the body from its precursors nicotinamide, nicotinic acid, and nicotinamide riboside (NR), as a group called "vitamin B3". Treatment of experimental A-T animal models with NR showed beneficial effects. The aim of this study is to investigate whether treatment with NR during a period of six months may have positive effects on the disease course of patients with A-T. Objective: To investigate the effects of NR on the disease course of patients with ataxia telangiectasia. Study design: Single center, interventional, explorative, open-label proof of concept study. Study population: Patients with A-T (age >2 years). Intervention (if applicable): Patients will be treated with nicotinamide riboside (25mg/kg/day), during four consecutive months, followed by a washout period of two months. Main study parameters/endpoints: Ataxia, dysarthria, quality of life, laboratory parameters.

Interventions

  • Dietary Supplement: Vitamin B3
    • capsules with niagen

Arms, Groups and Cohorts

  • Experimental: Intervention group
    • treatment with vitamin B3

Clinical Trial Outcome Measures

Primary Measures

  • Ataxia, SARA (Scale of the assesment and rating of ataxia)
    • Time Frame: change from baseline -1 month – 4 months – 6 months
    • Changes in the total score will be measured.
  • Ataxia, ICARS (International Cooperative Ataxia Rating Scale)
    • Time Frame: change from baseline -1 month – 4 months – 6 months
    • Changes in the total score will be measured.
  • Ataxia, 9-hole pegboard test.
    • Time Frame: change from baseline -1 month – 4 months – 6 months
    • Changes in fastes time of the 9-hole pegboard test will be measured.
  • Dysarthria, Radboud dysarthria assesment (RDA)
    • Time Frame: change from baseline -1 month – 4 months – 6 months
    • Changes in maximum performance tasks and severity of dysarthria will be measured.

Secondary Measures

  • Quality of life questionnaire EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L)
    • Time Frame: change from baseline -1 month – 4 months – 6 months
    • Changes in the total quality of life score will be measured.
  • Laboratory measurements
    • Time Frame: change from baseline -1 month – 4 months – 6 months
    • Results will be summarized descriptively, with abnormal and clinically notable values/findings being identified
  • Intelligibility, Intelligibility in Context Scale (ICS)
    • Time Frame: change from baseline -1 month – 4 months – 6 months
    • Changes in the total score of the Intelligibility in Context Scale (ICS), will be measured.
  • Fatigue, Visual Analogous Scale (VAS)
    • Time Frame: change from baseline -1 month – 4 months – 6 months
    • Changes in the total VAS score will be measured.

Participating in This Clinical Trial

Inclusion Criteria

  • A-T patients who visit our outpatient clinic. – Genetically confirmed diagnosis of A-T by the identification of pathogenic mutations of the ATM gene. – Age ≥ 2 years or older and bodyweight ≥ 12 Kg. – Informed consent. Exclusion Criteria:

  • Additional medical condition or illness that impair the patient's ability to participate in the study (e.g. actual treatment of a malignancy, active infection, poorly controlled diabetes mellitus, hypertension, organ failure, clinically significant hematological or biochemical abnormalities different from the usual abnormalities in A-T) – Elevated serum transaminases (> 2 times upper limit of normal) – Participation in another interventional study at start of the study or during the study – Pregnancy. – Breast feeding.

Gender Eligibility: All

Minimum Age: 2 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Radboud University
  • Collaborator
    • A-T childrens project
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Michel Willemsen, Prof., Principal Investigator, michel.willemsen@radboudumc.nl

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.